



GlycoMimetics, Inc.

Innovation Today, Healing Tomorrow.

## GlycoMimetics to Present at Jefferies 2019 Healthcare Conference

May 29, 2019

ROCKVILLE, Md.--(BUSINESS WIRE)--May 29, 2019-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a corporate update at the Jefferies 2019 Healthcare Conference, on June 5 at 2:00 p.m. ET. in New York, NY.

To access the live webcast and subsequent archived recordings for this presentation, please visit the GlycoMimetics website at [www.glycomimetics.com](http://www.glycomimetics.com).

### About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly owned drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including a company-sponsored Phase 3 trial in relapsed/refractory AML. GlycoMimetics has also completed a Phase 1 clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at [www.glycomimetics.com](http://www.glycomimetics.com).

Source: GlycoMimetics

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190529005708/en/>

Source: GlycoMimetics, Inc.

### Investor Contact:

Shari Annes

Phone: 650-888-0902

Email: [sannes@annesassociates.com](mailto:sannes@annesassociates.com)

### Media Contact:

Jamie Lacey-Moreira

Phone: 410-299-3310

Email: [jamielacey@presscommpr.com](mailto:jamielacey@presscommpr.com)